GWLL (Goldenwell Biotech) Long-Term Debt: $0.10 Mil (As of Mar. 2026)


GWLL Goldenwell Biotech Inc GWLL
30 GF Score
Price $0.90
! 1 Warning Sign
View Full Analysis

What is Goldenwell Biotech Long-Term Debt?

Goldenwell Biotech GWLL 30 Long-Term Debt is $0.10 Mil as of Mar. 2026. GuruFocus rates GWLL with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Goldenwell Biotech's Long-Term Debt for the quarter that ended in Mar. 2026 was $0.10 Mil.

Goldenwell Biotech's quarterly Long-Term Debt stayed the same from Sep. 2025 ($0.10 Mil) to Dec. 2025 ($0.10 Mil) and stayed the same from Dec. 2025 ($0.10 Mil) to Mar. 2026 ($0.10 Mil).

Goldenwell Biotech's annual Long-Term Debt stayed the same from Dec. 2023 ($0.10 Mil) to Dec. 2024 ($0.10 Mil) and stayed the same from Dec. 2024 ($0.10 Mil) to Dec. 2025 ($0.10 Mil).

Goldenwell Biotech  (OTCPK:GWLL) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Goldenwell Biotech Long-Term Debt Related Terms

Goldenwell Biotech Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Goldenwell Biotech's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Goldenwell Biotech Long-Term Debt Chart

Goldenwell Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.10 0.10 0.10

Goldenwell Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.10 0.10 0.10 0.10
GWLL
30GF Score
Goldenwell Biotech Inc GWLL
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.10 Mil mean?
Goldenwell Biotech (GWLL) has a Long-Term Debt of $0.10 Mil as of Mar. 2026.
Is Goldenwell Biotech's Long-Term Debt too high?
Goldenwell Biotech's current Long-Term Debt is $0.10 Mil. Overall, Goldenwell Biotech has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Goldenwell Biotech's Long-Term Debt compare to HAIN and LSF?
Goldenwell Biotech's Long-Term Debt of $0.10 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Consumer Packaged Goods company?
A good Long-Term Debt depends on the Consumer Packaged Goods industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Goldenwell Biotech's current Long-Term Debt is $0.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Goldenwell Biotech stock overvalued right now?
Goldenwell Biotech (GWLL) has a current Long-Term Debt of $0.10 Mil. The current Long-Term Debt is $0.10 Mil. Goldenwell Biotech's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Goldenwell Biotech (GWLL), the current Long-Term Debt is $0.10 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Goldenwell Biotech Business Description

Address 581 Boston Mills Road, Suite 300, Hudson, OH, USA, 44236
Goldenwell Biotech Inc is engaged in the research and development, production, and sales of healthcare and supplement products. Its products comprise JI MAI - Bovine Cardiac Vascular Active Peptide, Double Proline AG - 3D Active Collagen Peptide, Cartilage Peptide - Type II collagen peptide, and Sugar Master.
30GF Score

Get the complete analysis for GWLL

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.90
Price